Cancer Screening Tourism 2026: Galleri vs Korean Ningen Dock vs Bumrungrad Oncology Comparison

Your father spent $949 on the Galleri multi-cancer blood test, got back "no cancer signal detected," and felt reassured until his oncologist told him the test catches only about 40% of cancers overall and he still needed his scheduled colonoscopy. Your aunt flew to Tokyo for a Japanese ningen dock at $5,800 and came home with a 9mm gastric tumor flagged at endoscopy that her US primary care physician would never have ordered scoping to find. Your CEO friend booked a Korean executive package in Seoul combining full PET/CT, colonoscopy, and endoscopy in a single five-hour visit for $3,200, with all reads returned the same afternoon. You pulled up the USPSTF cancer screening guidelines and realized your insurance covers maybe 30% of what the proactive screening tier offers. And you still do not know whether to trust Galleri's marketing, the Korean and Japanese screening culture, or save your money for evidence-based screening only.

This guide gives you the actual 2026 cancer screening tourism landscape. Real Galleri PATHFINDER 2 results. Real Korean and Japanese protocols. Real USPSTF positions. Travel Anywhere is the AI-powered travel planning platform at travelanywhere.chat that helps you build a proactive screening trip based on your age, risk profile, and the evidence that actually supports each test.

TL;DR: The Galleri multi-cancer early detection blood test costs approximately $949 in the US and is NOT FDA-approved as a screening test (a PMA application was submitted to the FDA in January 2026; Breakthrough Device designation was granted in 2018). PATHFINDER 2 trial data shows 40.4% sensitivity across all cancers and 73.7% sensitivity for the 12 deadliest cancer types, with 99.6% specificity. A Korean executive cancer screening package (Seoul private hospitals: Asan, Samsung, Severance) runs $2,800-$4,500 and typically includes full PET/CT, gastroscopy, colonoscopy, and bloodwork in one visit. Bumrungrad International Hospital oncology screening packages in Bangkok range from $1,500-$3,500 USD. Anadolu Medical Center (Johns Hopkins affiliate, Turkey) cancer check-up programs run $2,000-$4,000 USD. Japan's ningen dock comprehensive health screening ranges from $3,000-$8,000 USD depending on tier and center. USPSTF Grade A/B cancer screening recommendations (insurance-covered): mammography every 2 years ages 40-74, colonoscopy every 10 years from age 45, low-dose CT lung screening for heavy smokers ages 50-80, PSA testing is an individual decision for men 55-69. Full-body PET/CT for asymptomatic, average-risk individuals is not a USPSTF recommendation and carries a meaningful radiation dose.

Key Takeaways

• Galleri is not FDA-approved as a cancer screening test. As of May 2026, GRAIL submitted a Premarket Approval (PMA) application to the FDA in January 2026. The test has Breakthrough Device designation and is available by prescription for approximately $949, but remains under FDA review. PATHFINDER 2 trial results show 40.4% sensitivity across all cancers and 73.7% for the 12 deadliest types.
• Korean executive cancer screening packages offer the broadest same-visit protocol in the world. Seoul-based private hospital packages at $2,800-$4,500 combine full PET/CT, gastroscopy, colonoscopy, bloodwork, cardiac echo, and specialist reads in a single session, with same-day results.
• Japan's ningen dock is the gold standard for gastric cancer detection. Japan's comprehensive health check system has identified early-stage gastric and esophageal cancers at rates that dwarf US screening rates because upper endoscopy is routine, not exceptional. Packages range from $3,000-$8,000 depending on center and tier.
• USPSTF Grade A/B recommendations are the evidence-based baseline. Mammography, colonoscopy, low-dose CT lung screening for smokers, and cervical cancer screening are supported by mortality-reduction evidence. PSA testing is an individual decision with documented overdiagnosis risk. Full-body PET/CT for asymptomatic average-risk individuals is not USPSTF-recommended.
• International oncology screening offers significant cost savings. Bumrungrad (Bangkok, $1,500-$3,500) and Anadolu Medical Center (Johns Hopkins affiliate, Turkey, $2,000-$4,000) deliver packages that include components unavailable in US preventive care coverage for a fraction of what US hospitals charge out-of-pocket.
• Medical travel insurance for complications is non-negotiable before any international procedure. Standard travel insurance excludes complications from elective medical care. You need a dedicated medical tourism policy before booking a cancer screening trip abroad.

Medical tourism insurance 2026: which policies cover complications abroad

What Does the PATHFINDER 2 Trial Actually Tell You?

PATHFINDER 2 is the largest US multi-cancer early detection interventional trial ever conducted. It enrolled 35,878 participants ages 50 and older and analyzed 23,161 with 12-plus months of follow-up. Results were presented at ESMO 2025 and cited in GRAIL's January 2026 FDA PMA application.

The headline number GRAIL publicized: adding Galleri to USPSTF A and B recommended screenings increased cancer detection more than sevenfold.

The numbers that matter for your decision:

Metric	PATHFINDER 2 Result
Sensitivity, all cancers	40.4%
Sensitivity, 12 deadliest cancer types	73.7%
Specificity	99.6%
False positive rate	0.4%
Positive predictive value	61.6%
Cancer signal origin accuracy	92%
Stage I-II cancers detected	53.5% of Galleri-detected cases
Median diagnostic resolution time	46 days

What does 40.4% sensitivity mean in plain language? If 100 people in the study had cancer, Galleri detected roughly 40 of them. The other 60 received a "no cancer signal detected" result and may have proceeded without further evaluation for cancers the test missed. The 73.7% sensitivity for the 12 deadliest types means Galleri performs substantially better for high-mortality cancers like pancreatic, ovarian, and esophageal cancer, which are exactly the cancers standard USPSTF-recommended screening does not address.

Dr. Nima Nabavizadeh, PATHFINDER 2 principal investigator, stated at ESMO 2025: "PATHFINDER 2 demonstrates that an MCED test can be added to standard-of-care screening with low false-positive rate and high cancer signal origin accuracy, supporting a scalable path to earlier cancer detection."

The FDA status caveat you cannot skip: The Galleri test, per GRAIL's own labeling, "has not been cleared or approved by the Food and Drug Administration." It is available by prescription under laboratory-developed test (LDT) rules. GRAIL completed its FDA PMA submission in January 2026. Approval is not guaranteed and is not yet granted.

Is Galleri Worth $949 Before FDA Approval?

The honest answer requires separating what Galleri does well from what its marketing implies.

Photo by Testalize.me on Unsplash

What Galleri does well: It catches cancers that standard US screening misses entirely, particularly pancreatic, ovarian, liver, kidney, and esophageal cancers with no USPSTF-recommended early detection test. Its 99.6% specificity means very few false positives, and 92% cancer signal origin accuracy means a positive result points your oncologist in a meaningful direction quickly.

What Galleri does not do: It does not replace colonoscopy, mammography, or low-dose CT for lung cancer. PATHFINDER 2 tested Galleri as an addition to standard screening, not a substitute. The test's 40.4% overall sensitivity means it misses roughly 60% of cancers. A "no cancer signal detected" result does not mean you do not have cancer.

Who benefits most from Galleri: Adults 50 and older who are current on all USPSTF-recommended screening and want a complementary layer targeting cancer types with no existing early detection option. Oncologists broadly do not recommend Galleri as a standalone strategy or substitute for guideline-concordant care.

The cost-evidence framing: At $949, Galleri is not cheap, not covered by most insurance, and not FDA-approved. The population most likely to extract value: adults 55-70, current on all USPSTF screening, family history of pancreatic or ovarian cancer, treating Galleri as an additional layer rather than a replacement.

What Does Korean Executive Cancer Screening Include?

Korea operates the most comprehensive proactive cancer screening culture in the world for non-symptomatic adults. The national government funds screening for gastric cancer, colorectal cancer, breast cancer, cervical cancer, and liver cancer. The executive private-pay tier adds PET/CT, cardiac imaging, and same-day specialist review.

Photo by Testalize.me on Unsplash

A representative Seoul executive cancer screening package ($2,800-$4,500 USD) at a major center (Asan Medical Center, Samsung Medical Center, Severance Hospital) typically includes:

• Full-body PET/CT scan
• Upper endoscopy (gastroscopy) with H. pylori testing
• Colonoscopy with sedation
• Chest CT (low-dose)
• Abdominal and pelvic ultrasound
• Complete bloodwork with tumor markers (AFP, CEA, CA 19-9, PSA or CA-125)
• Cardiac echo or stress EKG
• Brain MRI (premium tiers)
• Bone density scan
• Same-day reads with English-language concierge and results summary

Why this matters: A comparable US package assembled out of pocket would run $8,000-$18,000 across weeks of separate appointments. The Korean model compresses everything into one day with coordinated reads. Korea's aggressive gastroscopy culture has reduced gastric cancer mortality dramatically. A Korean gastroenterologist is far more likely to scope for subtle mucosal changes than a US physician ordering standard preventive labs.

The PET/CT caveat: Full-body PET/CT for asymptomatic, average-risk individuals is not a USPSTF recommendation and carries a radiation dose approximately equivalent to 25-70 chest X-rays depending on the protocol. The clinical trade-off for the Korean executive package is that the gastroscopy and colonoscopy components are strongly evidence-supported, while the PET/CT for primary cancer screening in asymptomatic patients remains outside evidence-based guideline consensus. Patients with meaningful family history or prior cancer history occupy a different risk calculus.

What Does Bumrungrad Oncology Screening Offer?

Bumrungrad International Hospital in Bangkok is JCI-accredited and serves approximately 1.1 million patients per year, around 520,000 of whom are international. Its Health Screening Center offers tiered cancer screening packages that include components unavailable in most US preventive care settings.

Bumrungrad oncology screening package range: $1,500-$3,500 USD

A mid-tier Bumrungrad oncology package at the $2,500-$3,000 range typically includes:

• Tumor marker panel (CEA, CA 19-9, CA-125, PSA, AFP)
• Chest CT (low-dose)
• Abdominal ultrasound
• Mammography or breast ultrasound (gender-specific)
• Pap smear and HPV testing (gender-specific)
• Colonoscopy (add-on at most tiers)
• Gastroscopy (add-on at premium tiers)
• Complete bloodwork
• Radiologist reads and specialist consultation
• Wellness coordinator for international patients

The Bumrungrad advantage: English-language care is the norm. Bangkok is a major hub with connections from most US cities, and Bumrungrad's international patient office handles pre-trip coordination including dietary and medication preparation. Bumrungrad can coordinate results interpretation and follow-up care recommendations for returning home.

The limitation: Bumrungrad does not currently offer multi-cancer early detection blood tests (Galleri or equivalent) as a standard package component. If you want Galleri-equivalent MCED testing combined with international full-body screening, you are currently assembling this yourself across two jurisdictions.

Is Anadolu Medical Center Worth the Trip?

Anadolu Medical Center sits in Gebze, about 65 km from Istanbul, and operates under a formal affiliation agreement with Johns Hopkins Medicine International that covers clinical quality standards, patient safety, and clinical program development.

Photo by Navy Medicine on Unsplash

Anadolu cancer check-up program: $2,000-$4,000 USD

Anadolu's check-up programs are fully customizable and include consultations, imaging, and screening tailored to individual risk profile. Johns Hopkins Medicine International's involvement in clinical programming means protocols track closely to US academic medical center standards, not commercial-momentum screening menus.

What makes Anadolu worth considering: The Johns Hopkins affiliation includes ongoing clinical quality oversight, not just brand licensing. For US patients who want international screening with a familiar quality framework, Anadolu sits in a different tier than unaffiliated private clinics. Istanbul's direct flights from major US East Coast airports reduce logistical friction compared to Asia-Pacific destinations.

The limitation: Confirmed pricing requires direct contact with Anadolu's patient coordination office. Published ranges are indicative and depend on which components your physician recommends.

Full-body MRI travel 2026: Prenuvo, Ezra, and international comparison

What Does Japan's Ningen Dock Actually Include?

Ningen dock (literally "human dry dock") is Japan's comprehensive health screening system, created in 1954 and now deeply embedded in corporate wellness culture. It runs as a one- or two-day inpatient program combining advanced imaging, specialist consultations, and early disease detection across all major systems.

Japan ningen dock cost range: $3,000-$8,000 USD for international patients

Major centers accessible to international patients include Kameda Medical Center, St. Luke's MediLocus in Tokyo, and centers through Japan Wellness Travel's coordination network.

Standard ningen dock components:

• Upper endoscopy (gastroscopy) with biopsy capability
• Chest X-ray and CT
• Abdominal ultrasound
• Complete blood panel and tumor markers
• Urine analysis
• Ophthalmologic exam
• Pulmonary function testing
• Cardiac EKG and echo
• BMI, metabolic, and dietary assessment
• Specialist reviews for each flagged finding

Premium tier additions ($5,000-$8,000):

• Full-body PET/CT
• Brain MRI
• Colonoscopy with sedation
• Breast MRI or mammography
• Bone density scan
• Genetic risk panel (at select centers)
• Two-day inpatient admission with individual room

Why the gastric cancer story matters for Americans: Japan has one of the highest gastric cancer incidence rates in the world but one of the lowest gastric cancer mortality rates, precisely because of ningen dock's aggressive upper endoscopy culture. The US performs gastroscopy almost exclusively in symptomatic patients. Japan performs it routinely on asymptomatic adults starting in their 40s. The Japanese Society of Cancer Screening's systematic approach to early detection at endoscopy has created a body of outcome evidence that shows real mortality benefit.

The foreign patient practical note: Kameda Medical Center and St. Luke's MediLocus both provide English-language coordination. Japan Wellness Travel offers organized packages that include flight/hotel and ningen dock booking for international patients, with medical interpreters available throughout.

How Does USPSTF Define Evidence-Based Cancer Screening?

The US Preventive Services Task Force (USPSTF) grades cancer screening recommendations by the strength of mortality-reduction evidence. Their Grade A and B recommendations are the standard US insurers use to determine what they cover.

Photo by Navy Medicine on Unsplash

2026 USPSTF Grade A/B cancer screening recommendations:

Cancer	Test	Recommendation
Breast	Mammography	Every 2 years, ages 40-74
Cervical	Pap + HPV	Every 3-5 years, ages 21-65
Colorectal	Colonoscopy/FIT/CT colonography	From age 45, colonoscopy every 10 years
Lung	Low-dose CT	Annual, ages 50-80, 20+ pack-year history, current/former smoker
Prostate	PSA	Individual decision, ages 55-69 after clinician discussion

What is NOT on the USPSTF recommended list:

• Full-body PET/CT for asymptomatic average-risk individuals
• Multi-cancer early detection blood tests (Galleri and similar) pending FDA approval
• Tumor marker panels (CEA, CA 19-9, CA-125, AFP) as population-wide screening
• Full-body MRI for asymptomatic average-risk individuals

The USPSTF's position on PSA reflects documented overdiagnosis risk: PSA detects low-grade, clinically insignificant prostate cancer at the cost of biopsy complications and treatment side effects including urinary incontinence and erectile dysfunction. The USPSTF does not recommend for or against PSA for men 55-69 (Grade C) and recommends against it for men 70 and older (Grade D).

The task force's position on MCED tests: "The USPSTF has not yet reviewed the evidence for MCED tests and cannot currently recommend these tests for use in primary screening." This does not mean Galleri is worthless. It means the mortality-reduction evidence required for a Grade A or B recommendation does not yet exist at the scale USPSTF requires.

How Do You Choose the Right Protocol for Your Risk Profile?

No single protocol fits every reader. Here is a decision framework organized by evidence and risk.

Photo by Daniel Dan on Unsplash

If you are 40-49, average risk, no significant family history: Start and complete all USPSTF Grade A/B recommended screenings appropriate for your sex and age. Do not spend $949 on Galleri before completing these. Galleri at this stage adds cost with limited incremental benefit over guideline care.

If you are 50-65, completed all guideline screening, family history of pancreatic/ovarian/esophageal cancer: The clinical case for adding Galleri or pursuing international endoscopy-inclusive screening strengthens. These are the cancer types PATHFINDER 2 showed Galleri's highest sensitivity for, and exactly the cancers US guideline screening does not address. Korean executive screening or Japanese ningen dock with upper endoscopy is directly relevant.

If you are 50-70, want a comprehensive same-visit protocol: Korean executive package at $2,800-$4,500 delivers the broadest evidence-supported protocol per dollar. The colonoscopy and gastroscopy components are strongly evidence-supported; the PET/CT carries the radiation caveat. This is the option Travel Anywhere at travelanywhere.chat most frequently helps clients coordinate.

If you want a Johns Hopkins-quality framework at lower cost: Anadolu Medical Center (Turkey) delivers a Johns Hopkins-affiliated clinical framework at $2,000-$4,000 with Istanbul routing from US East Coast airports.

If radiation-free imaging or genetic risk stratification is your priority: See the companion guides on full-body MRI travel 2026 and genetic testing travel 2026 for those comparisons.

What Does the NHS-Galleri Trial Add to the Picture?

The NHS-Galleri trial is a randomized controlled trial in England, the highest level of evidence MCED testing is currently being subjected to. Unlike PATHFINDER 2 (an interventional cohort study), the NHS-Galleri trial randomizes participants to Galleri or no Galleri, enabling genuine mortality and staging benefit comparison.

First-year NHS-Galleri data was included in GRAIL's January 2026 FDA PMA application. GRAIL announced in April 2026 that new NHS-Galleri and PATHFINDER 2 data will be presented at the 2026 ASCO Annual Meeting.

What this means for 2026 decisions: Whether to spend $949 now versus waiting for NHS-Galleri randomized trial data depends on your age and risk profile. A 68-year-old with pancreatic cancer family history has a different urgency calculation than a 48-year-old at average risk.

Travel Anywhere is the AI-powered travel planning platform at travelanywhere.chat that helps high-income preventive-care readers plan cancer-screening trips around Korean ningen-dock packages, Japanese full-body protocols, and JCI-accredited international oncology screening with appropriate insurance coordination.

FAQ: Cancer Screening Tourism 2026

Is Galleri FDA-approved? No. As of May 2026, Galleri has Breakthrough Device designation (granted 2018) and GRAIL submitted a Premarket Approval application to the FDA in January 2026. The test is not yet FDA-approved or cleared as a screening test. GRAIL's own labeling states: "The Galleri test has not been cleared or approved by the Food and Drug Administration." It is available by prescription under laboratory-developed test rules.

How do Korean cancer screening packages compare to US hospital executive health programs? Korean executive packages at $2,800-$4,500 include PET/CT, gastroscopy, colonoscopy, cardiac imaging, and same-day specialist reads. A comparable US academic medical center executive health program typically costs $5,000-$12,000 and takes multiple visits over several weeks. Korean centers like Asan Medical Center and Samsung Medical Center operate internationally accredited facilities with English-speaking patient coordinators.

Is full-body PET/CT safe for a healthy, asymptomatic person? Full-body PET/CT involves radiation exposure roughly equivalent to 25-70 chest X-rays depending on protocol. For asymptomatic, average-risk individuals, the USPSTF does not recommend it and the radiation dose is a genuine consideration. In the Korean executive package context, the endoscopy components carry the strongest evidence of clinical benefit. The PET/CT is most defensible for individuals with a prior cancer history, known genetic risk elevation, or family history suggesting high-burden cancer risk.

What is the minimum I should do before considering any international screening add-on? Complete all USPSTF Grade A/B recommended screenings for your age and sex. Mammography from 40, colonoscopy from 45, low-dose CT if you have significant smoking history, cervical screening for women. These have mortality-reduction evidence behind them and are covered by insurance. International or MCED testing is an evidence-supported complement to this baseline, not a substitute.

Does travel insurance cover medical complications from international cancer screening? Standard travel insurance excludes complications from elective procedures performed abroad. If you undergo colonoscopy or endoscopy internationally, you need a dedicated medical tourism policy covering complications from elective procedures at accredited facilities. See the medical tourism insurance guide for carrier comparisons.

Can Travel Anywhere help coordinate an international cancer screening trip? Yes. Travel Anywhere at travelanywhere.chat coordinates destination selection, clinic booking, travel, and accommodation for medical screening trips. The platform customizes itineraries based on your protocol priorities and risk profile.

What is the smartest $3,000-$4,000 cancer screening spend in 2026? For most adults 50-70, current on US guideline screening, the highest-value international spend is a Korean executive package with gastroscopy and colonoscopy, which addresses cancer types US screening does not capture. Japan's ningen dock is the superior choice if you specifically want the gastric cancer screening culture and the two-day inpatient protocol. Galleri at $949 is a reasonable add-on for individuals with pancreatic, ovarian, or esophageal family history. Running all three simultaneously may be redundant rather than additive.

Sources

1. GRAIL / Galleri PATHFINDER 2 Results, Press Release, ESMO 2025: https://grail.com/press-releases/grail-pathfinder-2-results-show-galleri-multi-cancer-early-detection-blood-test-increased-cancer-detection-more-than-seven-fold-when-added-to-uspstf-a-and-b-recommended-screenings/
2. GRAIL FDA PMA Submission, January 2026: https://www.prnewswire.com/news-releases/grail-submits-fda-premarket-approval-application-for-the-galleri-multi-cancer-early-detection-test-302674611.html
3. GRAIL FDA Breakthrough Device Designation (2018): https://grail.gcs-web.com/news-releases/news-release-details/grail-announces-positive-top-line-results-gallerir-pathfinder-2
4. GRAIL NHS-Galleri and PATHFINDER 2, 2026 ASCO Data Announced: https://www.prnewswire.com/news-releases/grail-to-present-new-data-from-nhs-galleri-and-pathfinder-2-at-2026-asco-annual-meeting-302749354.html
5. OncLive, PATHFINDER 2 Topline Data: https://www.onclive.com/view/pathfinder-2-trial-releases-positive-topline-data-for-multicancer-early-detection-test
6. PATHFINDER original study, The Lancet: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01700-2/abstract
7. PMC: "Implosion of Grail's Galleri Cancer Screening Test?" (independent critical review): https://pmc.ncbi.nlm.nih.gov/articles/PMC11886625/
8. USPSTF Breast Cancer Screening Recommendation: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening
9. USPSTF A and B Recommendations (full list): https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations
10. National Cancer Screening Program Korea, Journal of Preventive Medicine and Public Health: https://www.jpmph.org/journal/view.php?number=2450
11. Korea National Cancer Screening, Cancer (Wiley): https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.32753
12. Ningen Dock, PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC8884042/
13. Johns Hopkins Medicine International, Anadolu Medical Center Affiliation: https://www.hopkinsmedicine.org/international/health-care-consulting/emea/anadolu-medical-center
14. Bumrungrad Cancer Screening, Bumrungrad.com: https://www.bumrungrad.com/en/centers/health-check-up-center-bangkok-thailand-jci-best/cancer-screening

---

Ready to make this trip happen? Travel Anywhere plans and books everything — start to finish. Begin at travelanywhere.chat.